BioSpace News Archive

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on developing compounds that activate Tie2, and Aadi Bioscience, Inc., a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced their entry into a definitive merger agreement.

New Public Health Campaign Spotlights the Importance of Staying Up to Date with Recommended Vaccinations Against Vaccine-Preventable Diseases

Strategic acquisition will establish a European presence and grow Ginkgo’s Codebase of large-scale protein production capabilities

4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products - a novel class of drug derived from the microbiome, announced that it will present data from its Phase II study of single strain LBP Blautix® in patients with irritable bowel syndrome subtypes IBS-C and IBS-D in a poster session at Digestive Disease Week 2021, taking place virtually May 21-23, 2021.

Further Expands Charles River’s Scientific Capabilities in the High-Growth Cell and Gene Therapy CDMO Sector

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, announced the appointment of Jessie Hanrahan, Ph.D. as Chief Regulatory Officer.

Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, reported financial results for the first quarter of 2021 ended March 31, 2021 and provided an update on the Company’s recent and anticipated future developments.

VITALHUB CORP., is pleased to announce it has completed the acquisition of the on-premise hospital queue management business segment of Jayex Healthcare Limited, a leading UK and Australian e-health provider of integrated SaaS healthcare services delivery platforms.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit and present a corporate overview at the Oppenheimer Rare & Orphan Disease Summit.

Oxurion NV, a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in retinal vascular disorders, announces in a planned succession, the promotion of Tom Graney, CFA from Chief Financial Officer to Chief Executive Officer of the company.